About Ryan

Ryan Sansom centers his practice on advising privately held and publicly traded emerging companies, with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, healthcare IT and health and wellness. Ryan’s representation of life sciences and technology companies spans the entire emerging company life-cycle, including pre-incorporation planning, formation and founder matters, seed, venture capital and growth equity financings, public offerings and mergers and acquisitions, and other complex transactions. In addition, Ryan often represents venture capital firms in connection with their investments in emerging companies and underwriters in connection with public offerings by emerging companies.

View full bio

Experience

AllRock Bio Closes $50 Million Series A

AllRock Bio Closes $50 Million Series A

September 16, 2025

Cooley advised AllRock Bio, a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, on its $50 million Series A financing to advance AllRock’s lead molecule, ROC-101, a first-in-class, oral pan-rho-associated protein kinase inhibitor to treat pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.

Read more

Related contacts

Ryan Sansom
Partner, Boston
Barry Kuang
Associate, Boston
Danbi Kim
Associate, Boston
Christophe Beauduin
Partner, New York
Megan Boss
Senior Paralegal , Boston
Stephanie Gentile
Partner, New York

Related Practices & Industries

Emerging Companies
Biotechnology
Tax
Life Sciences Corporate Partnering and Licensing

Windward Bio Closes $200 Million Series A

Windward Bio Closes $200 Million Series A

January 10, 2025

Cooley advised Windward Bio, a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases, on its $200 million Series A financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Windward Bio.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Partner, Brussels

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Antitrust and Competition
Mergers and Acquisitions
Tax
Cyber/Data/Privacy

Alentis Therapeutics Closes $181.4 Million Series D

Alentis Therapeutics Closes $181.4 Million Series D

November 12, 2024

Cooley advised Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive tumors and organ fibrosis, on its $181.4 million oversubscribed Series D financing round. Partners Brandon Fenn and Ryan Sansom led the Cooley team advising Alentis Therapeutics.

Related contacts

Brandon W. Fenn
Partner, New York
Ryan Sansom
Partner, Boston
Alex Abelson
Associate, New York
Michael Bruno
Associate, New York
Robert Warshaw
Associate, New York
Xander Lee
Partner, Santa Monica
Kenneth Krisko
Partner, Reston

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences

Milestone Pharmaceuticals Enters Into Cooperation Agreement With Alta Fundamental Advisers

Milestone Pharmaceuticals Enters Into Cooperation Agreement With Alta Fundamental Advisers

July 16, 2024

Cooley advised Milestone Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, on its refreshment of its board of directors and cooperation agreement with Alta Fundamental Advisers.

Read more

Related contacts

Bill Roegge
Partner, New York
Ryan Sansom
Partner, Boston
Zachary Sonenshine
Associate, New York
Sarah Curry
Associate, New York
Samuel Paullin
Associate, Chicago

Related Practices & Industries

Activism Defense
Mergers and Acquisitions
View more

Admissions and credentials

Massachusetts

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.